Preeclampsia Diagnostics Market to Touch USD 1.24 Billion by 2029; Rising Prevalence of Preeclampsia to Propel Market Progress

The global preeclampsia diagnostics market size is expected to exhibit strong growth, reaching USD 1.24 billion by 2029. Fortune Business Insights™ in its report titled “Preeclampsia Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Test Type (Blood Tests and Urine Analysis), By Product (Instruments and Consumables), By End-user (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Regional Forecasts, 2022-2029” observes that the market size in 2021 stood at USD 1.03 billion and reached USD 1.07 billion by 2022. The market exhibited a CAGR of 2.2% during the forecast period. Furthermore, the increasing prevalence of preeclampsia and technological advancements in diagnostics procedures may propel the industry’s progress.

Ohio State University Wexner Medical Center Develops Novel Urine Test Kits to Foster Industry Growth

The Ohio State University “Wexner Medical Center developed novel test kits in March 2019. This launch may allow the company to examine preeclampsia at an earlier stage. This strategy may strengthen the university’s overall image and foster the industry's growth.

Strong Demand from the Healthcare Industry Bolstered Industry Growth

This market was positively impacted due to the healthcare industry's strong demand for preeclampsia diagnostics procedures. The increasing cases of preeclampsia elevated the procedure's adoption. Further, government guidelines for the diagnostics may enhance the product’s adoption. Moreover, market players witnessed a huge revenue spike due to increasing procedure adoption. For example, PerkinElmer Inc. witnessed a massive growth of 31.2% during 2020, touching USD 3,782.8 million. These factors may enhance industry growth.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/preeclampsia-diagnostics-market-101519

Advanced Preeclampsia Diagnostic Procedures’ Development to Enhance Industry Growth

Preeclampsia diagnostics are diagnostic procedures developed to protect infants and mothers from preeclampsia disorders. The development of innovative diagnostic procedures may bolster the diagnostic procedure adoption. The rising prevalence of the disorder in pregnant women globally is expected to enhance preeclampsia diagnostics’ adoption. For example, according to NCBI’s research, in July 2021, preeclampsia occurrence in France reached 8.5% among pregnant women. These factors may drive the market growth.

Major Players Provide Novel Products to Elevate Brand Image

Major players operating in the market introduce novel products to bolster the product demand. For example, PerkinElmer Inc. announced DELFIA Xpress sFIt PIGF 1-2-3 assay in July 2020. The kit aids in the treatment of disorders and preeclampsia predictions. This launch may allow the company to elevate its brand image. Further, major players adopt research and development to elevate diagnostics’ effectiveness and enhance safety. This strategy may allow players to boost their brand image.

Notable Industry Development

• July 2021 - LifeCell Diagnostics launched a comprehensive preeclampsia screening in India. The advanced screening detects biomarker, sFLT-1 (soluble FMS-like tyrosine kinase-1), which enables the prediction of the disease and helps in accurate diagnosis even in the third trimester.

List of Key Players Profiled in the Report

• F. Hoffmann-La Roche Ltd (Switzerland)
• PerkinElmer Inc. (Massachusetts, U.S.)
• DRG INSTRUMENTS GMBH (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Diabetomics, Inc. (U.S.)
• Metabolomic Diagnostics Ltd. (Ireland)
• Sera Prognostics (U.S.)
• Siemens Healthineers AG (Germany)
• Bayer AG (Germany)

Further Report Coverage

• The market in North America stood at USD 0.39 billion in 2021 and is expected to gain a huge portion of the global preeclampsia diagnostics market share. The adoption of technologically advanced products is expected to enhance the demand for the product.
• Furthermore, the rising awareness of the disease’s severity may enhance the demand for the product. Moreover, the increasing launch of technologically advanced products may enhance the product’s adoption. These factors may drive the industry’s progress.
• In Europe, the presence of a large patient pool suffering from hypertensive diseases may enhance the product’s demand. These factors may elevate industry growth.

Report Scope & Segmentation